A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively Selected Autologous Hematopoietic Stem Cells in Children With High-Risk Solid Tumors or Lymphomas. This evidence concerns the gene PROM1 and lymphoma.